11/20
08:06 am
kytx
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) had its price target lowered by analysts at HC Wainwright from $7.00 to $6.00. They now have a "neutral" rating on the stock.
Low
Report
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) had its price target lowered by analysts at HC Wainwright from $7.00 to $6.00. They now have a "neutral" rating on the stock.
11/17
08:19 am
kytx
institutional investors of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) must be disappointed after last week's 18% drop [Yahoo! Finance]
Low
Report
institutional investors of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) must be disappointed after last week's 18% drop [Yahoo! Finance]
11/15
03:26 pm
kytx
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) had its price target lowered by analysts at Wells Fargo & Company from $44.00 to $24.00. They now have an "overweight" rating on the stock.
Low
Report
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) had its price target lowered by analysts at Wells Fargo & Company from $44.00 to $24.00. They now have an "overweight" rating on the stock.
11/14
10:14 am
kytx
Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024 [Yahoo! Finance]
Medium
Report
Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024 [Yahoo! Finance]
11/14
10:01 am
kytx
Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024
Low
Report
Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024
11/13
04:22 pm
kytx
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
High
Report
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
11/13
04:14 pm
kytx
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
Medium
Report
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
10/21
08:00 am
kytx
Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors
Medium
Report
Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors
10/10
08:33 am
kytx
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $13.00 price target on the stock.
Low
Report
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $13.00 price target on the stock.
10/10
08:09 am
kytx
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.
Low
Report
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.
10/9
08:40 am
kytx
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $16.00 price target on the stock.
Medium
Report
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $16.00 price target on the stock.
9/19
08:08 am
kytx
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Medium
Report
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
9/18
08:00 am
kytx
Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024
Medium
Report
Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024
9/16
08:00 am
kytx
Kyverna Therapeutics Announces Leadership Update
Medium
Report
Kyverna Therapeutics Announces Leadership Update
9/12
11:59 pm
kytx
Three biotechs raise $700M in rare burst of IPO activity [Yahoo! Finance]
Medium
Report
Three biotechs raise $700M in rare burst of IPO activity [Yahoo! Finance]
9/11
11:00 am
kytx
Kyverna Therapeutics, Inc. May Have Committed Securities Fraud And The Schall Law Firm Encourages Shareholders To Join An Inquiry
Low
Report
Kyverna Therapeutics, Inc. May Have Committed Securities Fraud And The Schall Law Firm Encourages Shareholders To Join An Inquiry
9/10
11:00 am
kytx
The Schall Law Firm Is Looking Into Whether Kyverna Therapeutics Inc Violated Securities Laws And Investors Are Invited To Participate
Low
Report
The Schall Law Firm Is Looking Into Whether Kyverna Therapeutics Inc Violated Securities Laws And Investors Are Invited To Participate
9/9
11:00 am
kytx
Shareholders With Losses In Kyverna Therapeutics, Inc. Should Contact The Schall Law Firm About A Securities Fraud Investigation
Medium
Report
Shareholders With Losses In Kyverna Therapeutics, Inc. Should Contact The Schall Law Firm About A Securities Fraud Investigation
9/7
11:00 am
kytx
Kyverna Therapeutics Inc May Have Violated Securities Regulations And The Schall Law Firm Invites Investors To Join An Inquiry
Medium
Report
Kyverna Therapeutics Inc May Have Violated Securities Regulations And The Schall Law Firm Invites Investors To Join An Inquiry
9/6
11:00 am
kytx
Shareholders In Kyverna Therapeutics, Inc. Are Urged To Partake In The Schall Law Firm's Securities Related Investigation
Low
Report
Shareholders In Kyverna Therapeutics, Inc. Are Urged To Partake In The Schall Law Firm's Securities Related Investigation
9/5
11:00 am
kytx
The Schall Law Firm Is Looking Into Whether Kyverna Therapeutics Inc Committed Securities Fraud And Investors Should Join The Inquiry
Low
Report
The Schall Law Firm Is Looking Into Whether Kyverna Therapeutics Inc Committed Securities Fraud And Investors Should Join The Inquiry
9/4
11:00 am
kytx
Kyverna Therapeutics Inc. May Have Violated Securities Regulations And The Schall Law Firm Wants Stakeholders With Losses To Reach Out
Low
Report
Kyverna Therapeutics Inc. May Have Violated Securities Regulations And The Schall Law Firm Wants Stakeholders With Losses To Reach Out
9/3
11:00 am
kytx
The Schall Law Firm Is Looking Into Whether Kyverna Therapeutics Inc Committed Securities Fraud And Impacted Investors Are Urged To Play A Part
Medium
Report
The Schall Law Firm Is Looking Into Whether Kyverna Therapeutics Inc Committed Securities Fraud And Impacted Investors Are Urged To Play A Part
9/2
11:00 am
kytx
Kyverna Therapeutics Inc. May Be Liable To Compensate Investors And Those With Losses Should Contact The Schall Law Firm About An Inquiry
Medium
Report
Kyverna Therapeutics Inc. May Be Liable To Compensate Investors And Those With Losses Should Contact The Schall Law Firm About An Inquiry
9/1
11:00 am
kytx
The Schall Law Firm Wants The Public’s Contributions To An Investigation Into Whether Kyverna Therapeutics Inc Committed Securities Fraud
Medium
Report
The Schall Law Firm Wants The Public’s Contributions To An Investigation Into Whether Kyverna Therapeutics Inc Committed Securities Fraud